{"id":6070,"date":"2020-07-09T11:31:35","date_gmt":"2020-07-09T10:31:35","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=6070"},"modified":"2020-07-09T11:31:35","modified_gmt":"2020-07-09T10:31:35","slug":"five-generic-drugs-identified-as-preventative-treatments-for-covid-19","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/five-generic-drugs-identified-as-preventative-treatments-for-covid-19\/6070\/","title":{"rendered":"Five generic drugs identified as preventative treatments for COVID-19"},"content":{"rendered":"
CEBINA, an Austrian biotech company, has announced positive results of its new COVID-19 drug repurposing project<\/a>. The company has identified previously approved drugs as possible preventative treatments for COVID-19. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.<\/p>\n In collaboration with Professor Robert Konrat, a renowned structural biologist at University of Vienna<\/a>, CEBINA has applied a computational approach, integrating several software tools and novel biological pathway analysis, to identify potential preventative treatments for COVID-19.<\/p>\n